View Older Stories View More Recent Stories
-
BofA introduces Top 10 U.S. ideas for Q4 2025
-
Illumina partners with pharma companies on KRAS cancer diagnostics
-
Alnylam joins Alliance for Genomic Discovery genomic dataset
-
Illumina launches protein prep assay for drug discovery research
-
Illumina (ILMN) PT Raised at RBC Capital; 'Time For Investors To Re-Visit ILMN'
-
Stocks expected to have increasing option volume: ILMN BOOT FIVN ROKU KLAC NET SVV BE TREE BOOT KLAC PARA CSX PLTR
-
Illumina (ILMN) Tops Q2 EPS by 18c; offers guidance
-
Illumina launches enhanced cancer research assay with faster results
-
Scotiabank Downgrades Illumina (ILMN) to Sector Perform
-
Citi Downgrades Illumina (ILMN) to Sell
-
Evercore Lists Additions to TAP Outperform List of Life Science & Diagnostic Tools Names
-
Bernstein on US Life Science Tools & Diagnostics: 'Why We're More Bullish...'
-
iRhythm Technologies (IRTC) announces Board changes
-
Bernstein Reiterates Market Perform Rating on Illumina (ILMN) Post SomaLogic Acquisition
-
Illumina (ILMN) to acquire SomaLogic
-
Standard BioTools (LAB) Sells SomaLogic to Illumina (ILMN)
-
Illumina (ILMN) PT Raised to $99 at Canaccord Genuity Following CEO Podcast
-
Piper Sandler on Illumina (ILMN): 'Near-Term Headwinds, but We're Optimistic About 26/27'
-
Illumina (ILMN) unveils PromoterAI
-
Illumina (ILMN) expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
-
Stifel Reiterates Buy Rating on Illumina (ILMN)
-
Citi names 3 stocks as its new top picks in the Life Science sector
-
Illumina (ILMN) Launches DRAGEN v4.4 powers clinical oncology research and multiomic applications
-
Increasing unusual call option volume: PHAT CNH AXL RUN PPG SHLS AS AZUL ILMN
-
Illumina (ILMN) PT Lowered to $87 at Canaccord Genuity
-
These 2 sectors are under-owned, Barclays says and advises where to invest
-
Illumina (ILMN) PT Raised to $89 at TD Cowen Despite a 'Difficult Macro'
-
Illumina (ILMN) Tops Q1 EPS by 3c, provides guidance
-
Illumina (ILMN) and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
-
Piper Sandler on Illumina (ILMN): 'Buy This Dip'
-
Illumina (ILMN) and Tempus (TEM) partner to drive the future of precision medicine through genomic AI innovation
-
TD Cowen: 'We View Illumina (ILMN) as the Most Pressured'; PT Lowered to $86
-
Piper Sandler Reiterates Overweight Rating on Illumina (ILMN) Amid Headwinds in NGS
-
Bernstein's Take on Illumina (ILMN) Shaking Up the Board
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
Evercore ISI on Illumina (ILMN): 'Appointment of Keith Meister to BoD is an incremental positive'
-
Illumina (ILMN) Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
-
Activist Investor Meister To Join Illumina (ILMN) Board - WSJ
-
Illumina (ILMN) Announces Retirement of Chief Information Officer
-
Illumina (ILMN) PT Slashed to $128 at RBC Capital Following China Announcement
-
Illumina (ILMN) PT Lowered to $115 at Canaccord Genuity
-
Illumina (ILMN) addresses recent developments in China, updates guidance
-
Illumina (ILMN) Cuts 2025 Adjusted Earnings Guidance to $4.50 a Share - WSJ
-
Illumina (ILMN) PT Lowered to $90 at Baird
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
Barclays Reiterates Underweight Rating on Illumina (ILMN), PT $100
-
Evercore ISI Reiterates Outperform Rating on Illumina (ILMN)
-
Stifel Reiterates Buy Rating on Illumina (ILMN)
-
Wolfe Research Reiterates Outperform Rating on Illumina (ILMN), PT $150
